ADMA BIOLOGICS, INC. - Common Stock (ADMA) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
ADMA on Nasdaq
Shares outstanding
235,704,040
Price per share
$18.28
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
219,817,928
Total reported value
$4,009,232,116
% of total 13F portfolios
0.01%
Share change
-989,578
Value change
+$35,596,520
Number of holders
349
Price from insider filings
$18.28
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ADMA BIOLOGICS, INC. - Common Stock (ADMA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 15% $865,732,260 35,907,601 BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 8.9% $389,033,250 21,363,715 The Vanguard Group 30 Jun 2025
STATE STREET CORP 5.1% +6% $221,519,782 +$11,695,913 12,078,505 +5.6% STATE STREET CORPORATION 30 Jun 2025
Invesco Ltd. 5% -8% $211,308,672 -$19,394,917 11,785,202 -8.4% Invesco Ltd. 31 Dec 2025

As of 31 Dec 2025, 349 institutional investors reported holding 219,817,928 shares of ADMA BIOLOGICS, INC. - Common Stock (ADMA). This represents 93% of the company’s total 235,704,040 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of ADMA BIOLOGICS, INC. - Common Stock (ADMA) together control 71% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 15% 36,333,325 +2% 0.01% $662,719,847
VANGUARD GROUP INC 8.8% 20,854,669 -0.57% 0.01% $380,389,162
STATE STREET CORP 5.8% 13,597,259 +0.26% 0.01% $248,014,004
Invesco Ltd. 5% 11,785,202 -5.8% 0.03% $214,962,084
Sachem Head Capital Management LP 4.8% 11,375,000 +27% 4.9% $207,480,000
WESTFIELD CAPITAL MANAGEMENT CO LP 3% 6,992,907 +37% 0.53% $127,550,624
Capital Research Global Investors 2.8% 6,637,472 +104% 0.02% $121,067,489
Nuveen, LLC 2.5% 5,926,390 +3.5% 0.03% $108,097,353
GEODE CAPITAL MANAGEMENT, LLC 2.5% 5,830,941 +0.3% 0.01% $106,373,522
AMERICAN CENTURY COMPANIES INC 2.2% 5,198,379 +11% 0.05% $94,818,467
DIMENSIONAL FUND ADVISORS LP 2.1% 4,835,638 +0.78% 0.02% $88,203,657
UBS Group AG 1.9% 4,569,343 +130% 0.02% $83,344,816
JANUS HENDERSON GROUP PLC 1.7% 3,936,419 +3906% 0.03% $71,819,965
Thrivent Financial for Lutherans 1.6% 3,790,518 -8.5% 0.12% $69,139,000
Caligan Partners LP 1.3% 3,012,508 +14% 5% $54,948,146
FRANKLIN RESOURCES INC 1.2% 2,793,856 +40% 0.01% $50,959,932
B Group, Inc. 1% 2,457,542 +1.9% 33% $44,825,566
Ranger Investment Management, L.P. 0.98% 2,300,905 -1.7% 2.9% $41,968,507
NORTHERN TRUST CORP 0.96% 2,266,890 -4% 0.01% $41,348,074
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.96% 2,257,708 -4.4% 0.01% $41,180,594
AWM Investment Company, Inc. 0.93% 2,200,000 0% 3.9% $40,128,000
PRICE T ROWE ASSOCIATES INC /MD/ 0.92% 2,160,559 +0.23% 0% $39,410,000
Fundsmith LLP 0.89% 2,102,054 0.22% $38,341,465
VOYA INVESTMENT MANAGEMENT LLC 0.85% 2,012,096 +38% 0.04% $36,700,631
MORGAN STANLEY 0.83% 1,948,372 +34% 0% $35,538,324

Institutional Holders of ADMA BIOLOGICS, INC. - Common Stock (ADMA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 219,817,928 $4,009,232,116 +$35,596,520 $18.24 349
2025 Q3 218,118,383 $3,198,432,093 +$72,429,878 $14.66 360
2025 Q2 210,797,270 $3,837,973,056 +$78,904,738 $18.21 367
2025 Q1 205,274,525 $4,072,982,276 +$76,450,592 $19.84 342
2024 Q4 203,746,953 $3,496,535,119 -$114,107,061 $17.15 316
2024 Q3 207,372,865 $4,143,053,602 +$165,315,203 $19.99 300
2024 Q2 181,187,738 $2,025,731,155 +$84,927,207 $11.18 251
2024 Q1 174,472,998 $1,151,565,465 +$38,336,177 $6.60 213
2023 Q4 169,158,841 $764,627,025 -$2,944,733 $4.52 184
2023 Q3 171,151,086 $612,714,569 +$20,026,265 $3.58 188
2023 Q2 165,493,139 $610,610,254 +$2,418,775 $3.69 178
2023 Q1 165,334,603 $547,246,486 +$39,069,063 $3.31 161
2022 Q4 152,691,438 $592,428,828 +$84,016,367 $3.88 160
2022 Q3 129,844,191 $315,525,087 +$25,706,332 $2.43 126
2022 Q2 119,212,509 $236,039,706 +$28,768,170 $1.98 106
2022 Q1 104,891,672 $189,908,374 +$15,200,552 $1.83 101
2021 Q4 97,211,593 $137,058,638 +$69,617,810 $1.41 79
2021 Q3 41,605,720 $47,012,568 -$1,898,278 $1.13 65
2021 Q2 42,881,498 $68,611,517 -$9,321,193 $1.60 77
2021 Q1 48,542,943 $85,432,065 +$4,580,090 $1.76 99
2020 Q4 45,108,342 $87,965,210 -$3,255,262 $1.95 88
2020 Q3 46,229,823 $110,365,108 -$6,638,253 $2.39 89
2020 Q2 48,795,314 $143,056,287 +$1,125,669 $2.93 95
2020 Q1 48,452,749 $139,501,972 +$45,105,921 $2.88 90
2019 Q4 32,462,778 $129,848,396 -$5,342,106 $4.00 74
2019 Q3 37,184,714 $165,464,669 +$10,136,847 $4.45 71
2019 Q2 35,036,040 $135,582,245 +$49,523,348 $3.87 67
2019 Q1 22,292,511 $84,489,596 -$8,434,826 $3.79 54
2018 Q4 24,691,538 $57,976,000 -$3,589,136 $2.39 49
2018 Q3 26,643,107 $165,449,000 +$8,758,819 $6.21 56
2018 Q2 25,531,842 $115,150,787 +$41,337,517 $4.51 53
2018 Q1 16,954,991 $77,991,000 -$211,472 $4.60 34
2017 Q4 17,028,282 $54,659,000 +$27,531,457 $3.21 23
2017 Q3 8,453,450 $26,039,000 -$2,115,756 $3.08 17
2017 Q2 8,911,060 $33,198,000 -$1,175,766 $3.70 19
2017 Q1 9,228,077 $45,033,000 -$611,446 $4.88 17
2016 Q4 9,372,549 $47,987,000 -$550,899 $5.12 17
2016 Q3 9,476,278 $68,659,000 +$188,653 $7.24 18
2016 Q2 9,523,198 $57,439,000 +$6,745,061 $5.95 27
2016 Q1 8,389,293 $67,868,000 -$263,290 $8.09 21
2015 Q4 8,422,364 $67,999,000 -$508,297 $8.07 24
2015 Q3 7,050,136 $58,941,000 +$163,431 $8.36 23
2015 Q2 3,421,139 $31,680,000 +$720,804 $9.26 22
2015 Q1 6,949,700 $32,778,360 +$9,198,949 $9.80 18
2014 Q4 2,367,783 $26,447,585 +$14,273,703 $11.17 11
2014 Q3 776,863 $8,002,000 +$1,130,613 $10.30 1
2014 Q2 667,099 $6,504,000 +$6,504,000 $9.75 1